Armata Strengthens Phage Therapy Patents Ahead of Planned Phase 3 Trial

Key Points

• Armata announced two issued U.S. patents covering treatment methods involving its investigational bacteriophage candidates, AP-SA02 and AP-PA02.
• The AP-SA02 patent was issued October 6, 2026, with expected protection until at least February 2041.
• The AP-PA02 patent was issued April 7, 2026, with expected protection until approximately January 4, 2043.
• Armata’s global portfolio now includes 101 issued patents and 60 pending applications across 15 patent families.
• The company plans to initiate a Phase 3 superiority study of AP-SA02 in complicated Staphylococcus aureus bloodstream infections during the second half of 2026.

Armata Pharmaceuticals (NYSE: ARMP) has expanded its U.S. intellectual-property protection for two clinical-stage bacteriophage programs. The patents strengthen the company’s position as it prepares to advance lead candidate AP-SA02 into a planned Phase 3 study, but they do not establish clinical effectiveness or regulatory approval.

AP-SA02 Patent Covers Staphylococcus Infection Treatment

U.S. Patent No. 12,751,983, issued October 6, protects methods of treating Staphylococcus aureus infections using AP-SA02. Armata expects protection to extend until at least February 2041, with possible additional time through patent adjustments or extensions.

AP-SA02 is a fixed, multi-phage cocktail being developed as an add-on to antibiotic therapy for complicated S. aureus bacteremia, including infections caused by methicillin-sensitive and methicillin-resistant strains.

Armata said AP-SA02 has received FDA Qualified Infectious Disease Product, Fast Track and Breakthrough Therapy designations. Following previously reported positive Phase 2a results, the company plans to begin a Phase 3 superiority study in the second half of 2026.

AP-PA02 Patent Extends Into 2043

U.S. Patent No. 12,594,312, issued April 7, protects methods of treating Pseudomonas infections using AP-PA02. Its expected protection runs until approximately January 4, 2043, including 617 days of patent-term adjustment. Further extensions may be possible.

AP-PA02 is being developed for chronic respiratory infections caused by Pseudomonas aeruginosa in people with cystic fibrosis and non-cystic fibrosis bronchiectasis. Armata described results from its SWARM-P.a. and Tailwind Phase 2 trials as promising, though this announcement does not provide numerical efficacy findings.

Global Patent Portfolio Supports Phage Platform

Armata’s portfolio spans 15 patent families, with issued or pending claims covering its bacteriophage development programs. It includes 15 issued U.S. patents and 86 issued patents outside the United States, plus nine pending U.S. applications and 51 pending applications elsewhere.

The company said nominal expiration dates across the portfolio extend through 2046. That date applies to the broader portfolio—not necessarily to either newly announced patent.

Investor Takeaway: IP Protection Adds Value, but Trials Remain Critical

For ARMP investors, the patents provide longer-term protection around treatment methods involving two clinical candidates. They also support Armata’s strategy of protecting individual phage cocktails developed through its proprietary platform.

The nearer-term milestone remains initiation of the AP-SA02 Phase 3 study. Patent protection and FDA development designations do not guarantee trial success or approval, and the announcement provides no Phase 3 readout date, commercial forecast or revenue contribution from either candidate.